Prostaglandin E2 (
PGE2 ) has been implicated in counteracting fibroblast differentiation by TGFβ1 during
pulmonary fibrosis. However, the precise mechanism is not well understood. We show here that
PGE2 via EP2 R and EP4 R inhibits the expression of mechanosensory molecules
Lysyl Oxidase Like 2 (LOXL2),
myocardin-related
transcription factor A (MRTF-A), ECM
proteins,
plasminogen activation inhibitor 1 (PAI-1),
fibronectin (FN), α-smooth muscle actin (α-SMA), and redox sensor (
nicotinamide adenine dinucleotide phosphate (
NADPH) oxidase 4 (NOX4)) required for TGFβ1-mediated fibroblast differentiation. We further demonstrate that
PGE2 inhibits fibrotic signaling via Yes-associated
protein (YAP) but does so independently from its actions on SMAD phosphorylation and conserved cylindromatosis (CYLD;
deubiquitinase) expression. Mechanistically,
PGE2 phosphorylates/inactivates YAP downstream of EP2 R/Gαs and restrains its translocation to the nucleus, thus inhibiting its interaction with
TEA domain family members (TEADs) and transcription of fibrotic genes. Importantly, pharmacological or
siRNA-mediated inhibition of YAP significantly downregulates TGFβ1-mediated fibrotic gene expression and myofibroblast formation. Notably, YAP expression is upregulated in the lungs of D. farinae-treated wild type (WT) mice relative to saline-treated WT mice. Our results unravel a unique role for
PGE2 -YAP interactions in fibroblast differentiation, and that
PGE2 /YAP inhibition can be used as a novel therapeutic target in the treatment of pathological conditions associated with myofibroblasts like
asthma.